MMWR Morb Mortal Wkly Rep. 2013 Mar 1;62(8):145-7.
On June 24, 2012, CDC notified Public Health Services, County of San Diego Health and Human Services Agency, of a suspected case of vaccinia virus infection transmitted by sexual contact. The case had been reported to CDC by an infectious disease specialist who had requested vaccinia immune globulin intravenous (VIGIV) (Cangene Corporation, Berwyn, Pennsylvania) for a patient with lesions suspicious for vaccinia. The patient reported two recent sexual contacts: one with a partner who recently had been vaccinated against smallpox and a later encounter with an unvaccinated partner. Infections resulting from secondary transmission of vaccinia virus from the smallpox vaccinee to the patient and subsequent tertiary transmission of the virus from the patient to the unvaccinated partner were confirmed by the County of San Diego Public Health Laboratory. The smallpox vaccine had been administered under the U.S. Department of Defense smallpox vaccination program. The vaccinee did not experience vaccine-associated complications; however, the secondary and tertiary patients were hospitalized and treated with VIGIV. No further transmission was known to have occurred. This report describes the epidemiology and clinical course of the secondary and tertiary cases and efforts to prevent further transmission to contacts.
2012 年 6 月 24 日,疾病预防控制中心通知圣地亚哥县公共卫生服务和人类服务机构,有一例疑似天花病毒感染病例通过性接触传播。传染病专家向疾病预防控制中心报告了该病例,该专家曾请求为一名有疑似牛痘病变的患者使用静脉注射用牛痘免疫球蛋白(VIGIV)(宾夕法尼亚州伯温的 Cangene 公司)。患者报告了两次最近的性接触:一次是与最近接种过天花疫苗的伴侣,另一次是与未接种疫苗的伴侣。圣地亚哥县公共卫生实验室证实,天花疫苗接种者将天花病毒传给患者,随后患者将病毒再次传染给未接种疫苗的伴侣,导致继发和继发传播。天花疫苗是在美国国防部的天花疫苗接种计划下接种的。疫苗接种者没有出现与疫苗相关的并发症;然而,继发和继发患者住院并接受了 VIGIV 治疗。据报道,没有进一步的传播。本报告描述了继发和继发病例的流行病学和临床过程,以及为防止进一步传播给接触者所做的努力。